Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
4.025
+0.235 (6.22%)
Nov 21, 2024, 1:24 PM EST - Market open

Company Description

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.

Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.

The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205.

It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans.

In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen’s KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers.

Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Verastem, Inc.
Verastem logo
Country United States
Founded 2010
IPO Date Jan 27, 2012
Industry Biotechnology
Sector Healthcare
Employees 73
CEO Daniel Paterson

Contact Details

Address:
117 Kendrick Street, Suite 500
Needham, Massachusetts 02494
United States
Phone 781 292 4200
Website verastem.com

Stock Details

Ticker Symbol VSTM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001526119
CUSIP Number 92337C104
ISIN Number US92337C2035
Employer ID 27-3269467
SIC Code 2834

Key Executives

Name Position
Daniel W. Paterson President, Chief Executive Officer and Director
Daniel Calkins Chief Financial Officer and Principal Accounting and Financial Officer
Richard H. Aldrich M.B.A. Founder and Consultant
Dr. Robert A. Weinberg Ph.D. Co-Founder and Chair of Scientific Advisory Board
Dr. Piyush B. Gupta Ph.D. Co-Founder
Dr. Michelle Dipp M.D., Ph.D. Co-Founder
Dr. Jonathan Pachter Ph.D. Chief Scientific Officer
Cathy Carew Chief Organizational Effectiveness Officer
Nate Sanburn Chief Business Officer
Michael Crowther Chief Commercial and Strategy Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SCHEDULE 13G Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals